Stanford University
Showing 51-100 of 176 Results
-
Richard Hoppe
Henry S. Kaplan-Harry Lebeson Professor of Cancer Biology
Current Research and Scholarly InterestsIrradiation immunosuppression; total body irradiation;, psychosocial effects of cancer treatment; treatment of lymphoma;, mycosis fungoides.
-
Dimitre Hristov
Associate Professor of Radiation Oncology (Radiation Physics)
On Leave from 02/03/2025 To 03/11/2025Current Research and Scholarly InterestsDevelopment and integration of X-ray, MRI and US imaging technologies for radiation therapy guidance; Design of synergistic approaches to radiation therapy delivery; Treatment planning optimization and modeling.
-
Lu Ji
Postdoctoral Scholar, Radiation Biology
BioDriven by the enthusiasm and curiosity about life science and human disease, I have been working on cancer research for more than 5 years. I focus on developing novel therapeutic targets from tumor microenvironment and uncovering mechanisms of tumor progression, especially with expertise in gastrointestinal tumor biology and tumor microenvironment analysis. Now I'm digging into a field about finding a way to empower immunotherapy by appropriately utilizing radiation therapy.
-
Anusha Kalbasi, MD
Associate Professor of Radiation Oncology (Radiation Therapy)
BioDr. Kalbasi is a board-certified radiation oncologist and physician-scientist at the Stanford Cancer Institute. He is also an associate professor of radiation oncology at Stanford Medicine and a project member of the Parker Institute for Cancer Immunotherapy.
In the clinic, Dr. Kalbasi specializes in the diagnosis and treatment of solid tumors, especially sarcoma and melanoma, with a focus on bringing new treatments to patients. This focus includes using advanced techniques in radiation oncology and cancer immunotherapy.
Dr. Kalbasi's NIH-funded laboratory studies the cancer-immune interface in various therapeutic contexts, including T cell therapy, cytokine therapy and innate immune agonism. The lab has described tumor cell-, T cell- and myeloid cell-intrinsic mechanisms of resistance to therapy and approaches to overcome therapy resistance. Dr. Kalbasi is also an experienced leader of clinical trials related to immunotherapy, T cell therapy and radiation therapy.
Prior to his arrival at Stanford Health Care, Dr. Kalbasi was assistant professor of radiation oncology in the David Geffen School of Medicine at UCLA and chief of sarcoma radiotherapy at the UCLA Jonsson Comprehensive Cancer Center. During his tenure, he was named a NextGen Star by the American Association of Cancer Research in recognition for excellence in cancer research.
Dr. Kalbasi’s work has been published in leading journals including Nature, Science Translational Medicine, JAMA Oncology, Lancet Oncology, Nature Cancer and Cancer Discovery. He has served as a peer reviewer for multiple prestigious journals, including the Proceedings of the National Academy of Sciences, Cell and the Journal of Clinical Investigation. He has also presented research to his peers at the American Association for Cancer Research and the American Institute of Chemical Engineers. -
Daniel Kapp
Professor of Radiation Oncology, Emeritus
Current Research and Scholarly InterestsGynecologic malignancies; Rectal/and cancer; Breast Cancer; Hodgkin's disease; Hyperthermia; intraoperative radiation therapy; High dose rate radiation therapy; Predictive assays; Patterns of tumor spread; Health care finance.
-
Micah Kelly
Administrative Associate 3, Radiation Oncology - Radiation Biology
Current Role at StanfordAdministrative Associate to Drs. Erinn Rankin, Richard Frock, and Ted Graves
-
Susan Knox
Associate Professor of Radiation Oncology, Emerita
Current Research and Scholarly InterestsOur interests include 1) study of the effect of radiation on regulatory cell subpopulations and co-stimulatory molecules, 2) use of radiation as an immune modulator for optimization of transplant regimens, 3) the role of radiation in tumor vaccine strategies, 4) study of new radiosensitizers and radioprotectors, and 5) discovery of new targeted therapies for the treatment of solid tumors.
-
Nataliya Kovalchuk
Clinical Professor, Radiation Oncology - Radiation Physics
BioEducation:
2002 - B.S., Physics, Drohobych State University, Ukraine
2004 - M.S., Physics, Minnesota State University, Mankato, MN
2008 - Ph.D., Applied Physics, University of South Florida (H. Lee Moffitt Cancer Center and Research Institute), Tampa, FL
2010 - Medical Physics Residency, Mayo Clinic, Rochester, MN
Academic Appointments:
2010 - 2015 - Instructor, Harvard Medical School, Massachusetts General Hospital/Boston Medical Center, Department of Radiation Oncology, Boston, MA
2015 - 2019 - Clinical Assistant Professor, Stanford University, Department of Radiation Oncology, Stanford, CA
2019 - 2024 - Clinical Associate Professor, Stanford University, Department of Radiation Oncology, Stanford, CA
2019 - 2024 - Adjunct Associate Professor, MD Anderson Cancer Center/University of Texas, Houston, TX
2024 - present - Clinical Professor, Stanford University, Department of Radiation Oncology, Stanford, CA
2024 - present - Adjunct Professor, MD Anderson Cancer Center/University of Texas, Houston, TX -
Quynh-Thu Le, MD, FACR, FASTRO
Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Professor, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS)
Current Research and Scholarly InterestsMy laboratory focuses on identifying pathways and biomarkers of treatment resistance in head and neck cancer using clinical samples. We explore approaches to modulate these pathways through preclinical models (cell lines, organoids, tumor bearing mice) in order to develop precise strategies against these resistant mechanisms. At the same time, we are also studying pathways involved in treatment-related toxicity and develop strategies to prevent or overcome these toxicities.
-
Ruijiang Li
Associate Professor (Research) of Radiation Oncology (Radiation Physics)
Current Research and Scholarly InterestsMy lab's research is focused on the development of imaging and molecular biomarkers to improve cancer detection, diagnosis, prognostication, and prediction of therapy response. Our ultimate goal is to translate these biomarkers into clinical practice to guide optimal management and therapeutic decisions for precision cancer medicine.
-
Michael Lim, M.D.
Stanford Medicine Endowed Chair of the Department of Neurosurgery, Professor of Neurosurgery and, by courtesy, of Radiation Oncology, of Medicine, of Otolaryngology - Head & Neck Surgery (OHNS) and of Neurology and Neurological Sciences
BioDr. Lim is the Chair of the Department of Neurosurgery and a board-certified neurosurgeon specializing in brain tumors and trigeminal neuralgia.
Dr. Lim’s clinical interests include the treatment of benign and malignant brain tumors, with special interest in gliomas, meningiomas, metastatic tumors, and skull base tumors. Dr. Lim also specializes in surgical treatments for trigeminal neuralgia. During his time at Johns Hopkins, Dr. Lim built one of the largest brain tumor and trigeminal neuralgia practices and utilized the most advanced surgical technologies and techniques for his patients. As a passionate voice for patient experience, he has been recognized by his peers and patients for his integrity and compassionate care, including a Service Excellence Award from HealthNetwork Foundation.
As a mentor, he has garnered numerous teaching awards, including being honored as an outstanding teacher by Johns Hopkins University School of Medicine. He is actively involved in shaping education for neurosurgery and oncology across the United States and around the world. He is the recipient of the prestigious 2023 Abhijit Guha Award in Neuro-Oncology.
Dr. Lim’s research interests focus on harnessing the immune system to fight cancer. His laboratory focuses on understanding mechanisms of immune evasion by cancer cells. He has successfully translated his findings from the laboratory to the clinics and has conducted and led several large national immunotherapy clinical trials for brain tumors.
Dr. Lim’s bibliography contains well over 300 articles on topics such as immunotherapy for glioblastoma, long-term survival of glioma patients treated with stereotactic radiation, and treatment of neuropathic pain. His work has appeared in Science Translational Medicine, Clinical Cancer Research, Lancet Oncology, Nature Immunology, and many more publications. He also has written 20 book chapters and monographs.
Dr. Lim is a world leader in immunotherapy for brain tumors. In addition to being invited world-wide to give lectures and seminars, he has given platform presentations on the topics of immunotherapy for brain tumors, neurosurgical techniques and management of brain tumors at the American Society of Clinical Oncologists, American Academy of Neurological Surgeons, Radiological Society of North America, Annual Symposium on Brain and Spine Metastases, Congress of Neurological Surgeons, and other meetings. In addition, he has served as platform chairman of the CNS session at the American Society for Clinical Oncology conference.
Dr. Lim is a member of the American Society for Clinical Oncology, Congress of Neurological Surgeons, American Association of Neurological Surgeons, and Society for Neuro-Oncology. Dr. Lim served as the program co-chair of the Society for Neuro-Oncology and CNS section of the American Society for Clinical Oncology. He also served on many executive committees, including the Executive Committee for the Joint Tumor Section of the American Association of Neurological Surgeons and Congress of Neurological Surgeons.
Trigeminal neuralgia treatment: https://www.youtube.com/watch?v=-n8nvwkwZik
Trigeminal neuralgia patient stories: https://www.youtube.com/watch?v=kClePRPYlQs&t=1s -
Lianli Liu
Clinical Assistant Professor, Radiation Oncology - Radiation Physics
Current Research and Scholarly InterestsAI-driven medical imaging for accelerated imaging speed and improved image quality, including:
Accelerated imaging for in-treatment patient monitoring and post-treatment patient follow up;
Functional imaging for treatment response evaluation and prediction.
Optimizing clinical quality assurance workflow through AI, including:
Radiation beam data modeling for efficient commissioning;
Model-based error detection for accurate dosimetry. -
Billy W Loo, Jr, MD PhD FASTRO FACR
Professor of Radiation Oncology (Radiation Therapy)
Current Research and Scholarly InterestsMy clinical specialty is precision targeted radiotherapy of thoracic cancers.
My research is on developing next-generation ultra-rapid radiation therapy technology (PHASER) and studying the radiobiological effects of FLASH treatment.
My clinical research is on advanced 4-D image-guided radiation therapy and stereotactic ablative radiotherapy (SABR), and functional and metabolic imaging and imaging biomarkers. -
Gary Luxton
Professor of Radiation Oncology at the Stanford University Medical Center, Emeritus
Current Research and Scholarly Interests1. Mathematical modeling of damage to tumors and normal tissues from irradiation.
2. Image-guided intensity-modulated radiotherapy.
3. Modeling the combined radiobiological effect of brachytherapy and external beam irradiation.
4. Development of clinical hypofractionated extracranial radiosurgery. -
Vivek Maradia
Postdoctoral Scholar, Radiation Therapy
Current Research and Scholarly InterestsI research ultra-high dose rate delivery using proton, x-ray, and electron beams for FLASH preclinical studies, aiming to understand efficacy and safety mechanisms. My work aims to transform cancer therapy and enhance patient outcomes. Leveraging insights from PSI's PROScan facility, I design a compact cyclotron-based proton therapy infrastructure for various radiation therapy setups.
-
Carol Marquez, MD
Clinical Professor, Radiation Oncology - Radiation Therapy
BioDr. Marquez is a radiation oncologist and the medical director of the Stanford Cancer Center in South Bay. She has board certification in therapeutic radiology and completed fellowship training in the use of radioimmunotherapy and radiosensitizers.
Dr. Marquez educates future specialists in her position as a clinical professor in the Department of Radiation Oncology at Stanford University School of Medicine.
In her clinical practice, she specializes in breast cancer, but treats a broad spectrum of cancers including prostate, lung, colon, lymphoma, and brain tumors. For each patient, she develops a comprehensive, compassionate care plan customized to individual needs. Her goal is to deliver the most effective cancer treatment to help patients enjoy the best possible health and quality of life.
Dr. Marquez has conducted research and published numerous articles in peer-reviewed journals: Clinical Cancer Research, Annals of Surgical Oncology, the Journal of Women’s Health, and others. Topics include innovations in surgical decision-making, advanced treatment of prostate cancer, and the effectiveness of stereotactic body radiation therapy (SBRT) in treating larger brain tumors.
She also wrote the chapter on pediatric radiation therapy for the Textbook of Clinical Pediatrics.
She has made presentations to her peers at the annual meeting of the American Society for Therapeutic Radiology (ASTRO) and at the annual Radiation Oncology Conference. Topics include radiation therapy after a mastectomy and advanced management of cancer of the central nervous system
She received a grant to examine the recruitment and retention of minority patients in cancer research. The National Cancer Institute sponsored the study.
Dr. Marquez is a member of the American Society for Therapeutic Radiology, American College of Radiology (ACR), and Society for Neurologic Oncology (SNO). She is a Fellow of the American College of Radiology (FACR).
She participates on multiple committees in the Stanford School of Medicine Clinical Educator Program. She also serves as a radiation oncology expert on the Global Online Breast Tumor Board. This board is sponsored by Massachusetts General Hospital and meets monthly to provide real-time expert opinions for breast cancer cases from cancer centers across the world, including Brazil, Poland, and the Philippines. -
Andrew Philip Martella
Clinical Associate Professor, Radiation Oncology - Radiation Therapy
BioDr. Martella is a fellowship-trained radiation oncologist and a clinical assistant professor of radiation oncology at Stanford University School of Medicine.
His clinical interests include gynecologic, breast, thoracic, gastrointestinal, genitourinary, and central nervous system cancers. His experience encompasses the full range of radiotherapy techniques, including intensity modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), stereotactic body radiotherapy (SBRT), CyberKnife radiosurgery, eye plaque brachytherapy, and prostate and gynecologic high dose rate (HDR) brachytherapy.
Dr. Martella is dedicated to improving the quality of care and the patient experience. He deeply values a close relationship with his patients and their loved ones. He feels that each patient experiences healthcare in a unique and individual way. By recognizing and responding to those individual needs Dr. Martella provides a truly patient-centered experience. He has helped conduct research into noninvasive deep brain stimulation and chromosomal topography,and published on the topic of treating rectal cancer without radiation. He also was the primary contributing author of chapters in the book First Aid for the United States Medical Licensing Examination.
Dr. Martella has delivered presentations at the Annual Meeting of the American Society for Therapeutic Radiology and Oncology. Topics include chemotherapy and radiotherapy in endometrial cancer.
Among the honors for scholarship that Dr. Martella has received, he graduated first in his class at Duke University School of Medicine. He was also elected during medical school into Alpha Omega Alpha Honor Medical Society.
Dr. Martella’s community service has included a position on the board of directors of Camp Good Days and Special Times, a nonprofit organization that provides services for children who have cancer, have a parent or sibling with cancer, or have lost a parent or sibling to the disease. He has served on several leadership roles and has a deep dedication to furthering diversity and inclusion throughout the healthcare system.